Initial ColoSTAT Assessment in UK opens new market access

Summary by 6ix AI

Rhythm Biosciences Limited has announced the completion of the first phase of the ColoSTAT assessment by the Southern Hub research laboratory at the Royal Surrey NHS Foundation Trust, marking a significant step towards international market access. The successful technology transfer allows the Hub team to operate the ColoSTAT assay independently, which is crucial for the company's strategy to establish laboratory partnerships globally. The next steps include an analytical evaluation of the assay followed by a clinical study to confirm its reliability in detecting bowel cancer. This development positions Rhythm Biosciences to pursue opportunities beyond Australia, as the company aims to expand its diagnostic capabilities internationally.

Written by 6ix AI from the company’s filing. How 6ix writes summaries